FDA Offers to Trade Faster Drug Reviews for Lower US Prices

Marty Makary, a commissioner of the Food and Pharmaceutical Administration, said that the agency “equalizes” the cost of drugs between the US and other countries, can quickly monitor new drugs from pharmaceutical companies, which are an unusual proposal prevented from regulatory pricing debates.

David Westin and Bloomberg Television’s comments in an interview with the Wall Street Week give information about an idea to help the management of President Donald Trump realize one of the main health goals: foreign countries do not make a better agreement on drugs. Trump asked Americans to receive similar or lower prices with consumers in other countries with the order of execution signed in May.

Price arrangements can give companies another way to obtain “national priority coupons, and the award, which has been a part of a new program announced last month, will cut off the investigation periods for companies that it supports. Makary did not provide details about how drug producers should set their prices to set a row.

“We can publish a national priority review coupon for companies promising the price between what the US and other foreign countries pay,” Makary said. “We want to encourage good behavior in the market, and these priority coupons are worth a lot of money.”

The agency said that the new coupons will reduce the investigation periods from an average to one year to one year to one year. In the interview, Makary said the program can be used as a tool to equalize drug prices in places like Europe.

The Ministry of Health and Human Services asked drug producers, at least 60% of the US size of the United States, which has the lowest level of general competition offered in the economic cooperation and development organization with an economy per capita.

FDA typically refrained from bringing itself into the dark world of drug pricing in the USA. Clearly faster examinations for price changes in existing treatments will be abnormal for the agency, which does not have the authority to yarat research or control the prices collected for marketed drugs ”.

It is also unclear how much the coupons will have. Makary has revealed the value of pediatric priority examination coupons, which are currently offered within a different program that has ended. He said that some have been sold more than $ 100 million in a legal market. New national priority coupons cannot be sold.

Drug producers ultimately have a limited check on what patients are finally paying, where a complex insurance companies and drug assistance managers work between a patient prescribed typically, and where they take their medication from a pharmacy.

Nevertheless, the approach can offer a financial incentive to reduce drug prices of drug producers. When Trump maintained equalization costs with those abroad in the United States, he used only a more punishment approach and organized regulations paying Medicare, a health insurance program for the elderly and the disabled, for drugs managed in the doctor’s offices.

In the first statement of the coupon program, the FDA said that he could offer to return drug production to the USA, to address health crises or unlocked public health needs or to offer innovative treatments.

The interview will be released on Friday at 18:00 in New York.

This article was created from an automatic news agency feeding without changing the text.